Pakistan TB control program improves drug access

10 December 2007

The National Tuberculosis Control Program in Pakistan has reported that nationwide coverage was achieved in 2005 of the DOTS (Directly-Observed Treatment, Short Course), the World Health Organization-endorsed therapeutic strategy, designed to ensure patients take their medicines properly, and which has proven effective in preventing drug resistance. Speaking at a review of Pakistan's Ministry of Health and its component programs, Hassan Sadiq, the NTCP manager, noted that TB detection had improved to 70% and treatment success to 87%.

The positive news was partly the result of cooperation with the Global Fund to Fight AIDS, Tuberculosis and Malaria and the WHO, according to a report in the Pakistan-based International Times newspaper. The Global Fund has pledged $56.0 million in aid to Pakistan over five years, Mr Sadiq said. According to Ministry of Health figures, 280,000 people contract TB in Pakistan each year, with about 62,000 fatalities.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight